The association between metabolic surgery and remission of type 2 diabetes (T2D) is well established by several randomized controlled trials (RCTs) and observational studies, demonstrating that metabolic surgery is superior to medical treatment of T2D. Strengthening the Reporting of Observational Studies in Epidemiology T2D, Scandinavian Obesity Surgery Registry SOS, Gastric Bypass to Treat Obese Patients With Steady Hypertension HR, None of the mentioned disclosures were related to the contents of this work. IN has received consultant fees from Baricol Bariatrics AB and Johnson & Johnson Medical.
![spss 23 trial spss 23 trial](https://windows-cdn.softpedia.com/screenshots/IBM-SPSS-Amos_8.png)
JO has received consultant fees from Vifor Pharma AB, and Johnson & Johnson Medical. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Ĭompeting interests: I have read the journal’s policy and the authors of this manuscript have the following competing interests: ES has received lecturing fees from Johnson & Johnson Medical. EN received grants from Stockholm County Council and SRP Diabetes. Data are available from the Scandinavian Obesity Surgery Registry (contact via the Swedish Board of Health and Welfare (contact via and Statistics Sweden (contact via for researchers who meet the criteria for access to confidential data.įunding: ES received grants from Region Örebro County (Grant number: OLL-939106) and the Bengt Ihre Foundation. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.ĭata Availability: Data cannot be shared publicly because of patient confidentiality under current Swedish legislation. Received: MaAccepted: SeptemPublished: November 1, 2021Ĭopyright: © 2021 Stenberg et al. PLoS Med 18(11):Īcademic Editor: Sanjay Basu, Harvard Medical School, UNITED STATES (2021) Remission, relapse, and risk of major cardiovascular events after metabolic surgery in persons with hypertension: A Swedish nationwide registry-based cohort study. The main limitations of the study were missing information on nonpharmacological treatment for hypertension and the observational study design.Ĭitation: Stenberg E, Marsk R, Sundbom M, Ottosson J, Jernberg T, Näslund I, et al.
![spss 23 trial spss 23 trial](https://burndry.weebly.com/uploads/1/2/6/7/126775321/700422115.jpg)
![spss 23 trial spss 23 trial](https://www.researchgate.net/profile/Muhammad-Aslam-23/publication/331529410/figure/tbl2/AS:733257779929090@1551833686992/Study-characteristics.png)
After adjustment for age, sex, BMI, comorbidities, and education, the cumulative probabilities of MACEs (2.8% versus 5.7%, adjusted odds ratio (OR) 0.60, 95% confidence interval (CI) 0.47 to 0.77, p < 0.001) and all-cause mortality (4.0% versus 8.0%, adjusted OR 0.71, 95% CI 0.57 to 0.88, p = 0.002) were lower for patients being in remission at 2 years compared with patients not in remission, despite relapse of hypertension in 2,089 patients (cumulative probability 56.3%) during 10-year follow-up. High weight loss and male sex were associated with higher chance of remission, while duration, number of antihypertensive drugs, age, body mass index (BMI), cardiovascular disease, and dyslipidemia were associated with lower chance.
![spss 23 trial spss 23 trial](https://europepmc.org/articles/PMC6749174/bin/nava049481.va.jpg)
Of the 15,984 patients with pharmacologically treated hypertension, 6,286 (39.3%) were in remission at 2 years. Through cross-linkage with the Swedish Prescribed Drug Register, Patient Register, and Statistics Sweden, individual data on prescriptions, inpatient and outpatient diagnoses, and mortality were retrieved. All adults who underwent metabolic surgery between January 2007 and June 2016 were identified in the nationwide Scandinavian Obesity Surgery Registry (SOReg).